References

Filters: Akiyama-2019b is   [Clear All Filters]
Y
Yeh WW, Feng HP, Auger P, et al. Drug-drug interactions with grazoprevir/elbasvir: practical considerations for the care of HIV/HCV coinfected patients [abstract 63]. Presented at the International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington, DC; May 26-28, 2015.
Yehia BR, Schranz AJ, Umscheid CA, Lo Re, V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9(7):e101554.
Yeung LT, To T, King SM, Roberts EA. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepat. 2007;14:797-805.
Yoneda M, Saito S, Ikeda T, et al. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat. 2007;14(9):600-607.
Yoshida EM, Kwo P, Agarwal K, et al. Persistence of virologic response after liver transplant in hepatitis C patients treated with ledipasvir/sofosbuvir plus ribavirin pretransplant. Ann Hepatol. 2017;16(3):375-381.
Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment. Pharmacol. Ther. 2015;41(6):544-563.
Younossi ZM, Stepanova M, Sulkowski MS, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis. 2015;212(3):367-377.
Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol. 2016;111(6):808-816.
Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology. 2015;61(5):1471-1478.
Younossi ZM, Stepanova M, Jacobson I. Not achieving sustained viral eradication of hepatitis C virus after treatment leads to worsening of patient-reported outcomes. Clin Infect Dis. 2019:pii: ciz243. doi:10.1093/cid/ciz243.
Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology. 2014;59(6):2161-2169.
Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016;65(1):33-39.
Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014;12(8):1349-1359.
Younossi ZM, Zheng L, Stepanova M, Venkatesan C, Mir HM. Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2013;37(7):703-709.
Younossi ZM, Stepanova M, Afdhal NH, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63(2):337-345.
Z
Zahnd C, Salazar-Vizcaya LP, Dufour JF, et al. Impact of deferring HCV treatment on liver-related events in HIV+ patients. In: Conference on Retroviruses and Opportunistic Infections (CROI) February 23-26. Conference on Retroviruses and Opportunistic Infections (CROI) February 23-26. Seattle, WA; 2015.
Zahnd C, Salazar-Vizcaya LP, Dufour JF, et al. Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men. J Hepatol. 2016;65(1):26-32.
Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998;28(1):27-33.
Zelenev A, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. Lancet Infect Dis. 2018;18(2):215-224. doi:10.1016/S1473-3099(17)30676-X.
Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 Infection. N Engl J Med. 2018;378(4):354-369. doi:10.1056/NEJMoa1702417.
Top